002821 Asymchem Laboratories(Tianjin)Co.,Ltd.
Closed 02-25 15:00:00
99.54
+0.18
+0.18%
High100.33Low98.00Vol2.93M
Open98.84D1 Closing99.36Amplitude2.35%
Mkt Cap35.93BTradable Cap31.55BTotal Shares361.00M
T/O290.00MT/O Rate0.92%Tradable Shares317.00M
P/B2.07ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BRIEF-Citigroup's Long Position In H-Shares Of Asymchem Laboratories (Tianjin) Increases To 11.67% On Feb 19 From 9.34%, HKEX Filing Shows
Reuters  ·  02-25 19:45
BRIEF-Citigroup's Long Position In H-Shares Of Asymchem Laboratories (Tianjin) Increases To 11.67% On Feb 19 From 9.34%, HKEX Filing Shows
Citigroup's Long Position in H-Shares of Asymchem Laboratories (Tianjin) Increases to 11.67% on Feb 19 From 9.34% - HKEX
THOMSON REUTERS  ·  02-25 19:31
Citigroup's Long Position in H-Shares of Asymchem Laboratories (Tianjin) Increases to 11.67% on Feb 19 From 9.34% - HKEX
JPMorgan Boosts Stake in Asymchem with 9,400 Share Purchase at HK$87.56 Each
Stock News  ·  02-13
JPMorgan Boosts Stake in Asymchem with 9,400 Share Purchase at HK$87.56 Each
AsymBio Launches Integrated Biopharma Platforms for End-to-End Development
Reuters  ·  02-10
AsymBio Launches Integrated Biopharma Platforms for End-to-End Development
JPMorgan Increases Stake in Asymchem Laboratories by 4,700 Shares at HK$80.68 Per Share
Stock News  ·  02-09
JPMorgan Increases Stake in Asymchem Laboratories by 4,700 Shares at HK$80.68 Per Share
Norges Bank Increases Stake in Asymchem by 53,500 Shares at HK$79.01 Each
Stock News  ·  02-06
Norges Bank Increases Stake in Asymchem by 53,500 Shares at HK$79.01 Each
JPMorgan Trims Stake in Asymchem by 19,800 Shares at HK$78.64 Each
Stock News  ·  02-06
JPMorgan Trims Stake in Asymchem by 19,800 Shares at HK$78.64 Each
JPMorgan Trims Asymchem Stake by 7,800 Shares at HK$80.84 Per Share
Stock News  ·  02-03
JPMorgan Trims Asymchem Stake by 7,800 Shares at HK$80.84 Per Share
Norges Bank Increases Stake in Asymchem (06821) by 99,700 Shares at HK$80.67 Per Share
Stock News  ·  01-29
Norges Bank Increases Stake in Asymchem (06821) by 99,700 Shares at HK$80.67 Per Share
Asymchem (06821) Issues 281,300 Shares Under H-Share Restricted Stock Plan
Stock News  ·  01-26
Asymchem (06821) Issues 281,300 Shares Under H-Share Restricted Stock Plan
Norges Bank Reduces Stake in Asymchem by 110,000 Shares at HK$88.2 Each
Stock News  ·  01-19
Norges Bank Reduces Stake in Asymchem by 110,000 Shares at HK$88.2 Each
Schroders PLC Reduces Stake in Asymchem by 167,700 Shares at HK$83.63 Per Share
Stock News  ·  01-13
Schroders PLC Reduces Stake in Asymchem by 167,700 Shares at HK$83.63 Per Share
Schroders PLC Reduces Stake in Asymchem, Selling 260,500 Shares at HK$82.71 Per Share
Deep News  ·  01-11
Schroders PLC Reduces Stake in Asymchem, Selling 260,500 Shares at HK$82.71 Per Share
Schroders PLC Reduces Stake in Asymchem by 260,500 Shares at HK$82.71 Per Share
Stock News  ·  01-09
Schroders PLC Reduces Stake in Asymchem by 260,500 Shares at HK$82.71 Per Share
471 Shenzhen Market Companies Lead "Quality and Return Enhancement" Initiative, Dividend Payout Ratio Rises Nearly 11 Percentage Points in 2 Years
Deep News  ·  2025-12-27
471 Shenzhen Market Companies Lead "Quality and Return Enhancement" Initiative, Dividend Payout Ratio Rises Nearly 11 Percentage Points in 2 Years
Asymchem Laboratories Cuts Buyback Price Under 2025 Share Scheme; Shares
MT Newswires Live  ·  2025-12-22
Asymchem Laboratories Cuts Buyback Price Under 2025 Share Scheme; Shares
Asymchem (06821) to Repurchase and Cancel 33,000 Restricted A Shares
Stock News  ·  2025-12-19
Asymchem (06821) to Repurchase and Cancel 33,000 Restricted A Shares
Asymchem Laboratories Announces Repurchase and Cancellation of Restricted A Shares
Reuters  ·  2025-12-19
Asymchem Laboratories Announces Repurchase and Cancellation of Restricted A Shares
Pharmaceutical Stocks Rebound Sharply This Morning with Asymchem and Wuxi Biologics Both Rising Over 6%
Deep News  ·  2025-12-19
Pharmaceutical Stocks Rebound Sharply This Morning with Asymchem and Wuxi Biologics Both Rising Over 6%
AsymBio Launches Commercial Operations at Fengxian Base
Reuters  ·  2025-12-08
AsymBio Launches Commercial Operations at Fengxian Base

Introduction

Company Name.
凯莱英医药集团(天津)股份有限公司
Industry:
医药制造业
Listing Date:
2016-11-18
Main Business:
　　凯莱英医药集团(天津)股份有限公司的主营业务是为国内外制药公司、生物技术公司提供药品全生命周期的一站式服务。公司的主要产品是临床阶段CDMO解决方案、商业化阶段CDMO解决方案、新兴服务。截至报告期末公司共有国内外已授权专利538项，其中国内专利423项，国外专利115项，其中183项在合成生物领域，204项在连续反应技术领域。
Issue price:
30.53